Approved April, 2004
Apokyn (apomorphine) is a non-ergoline dopamine agonist. Formulations of apomorphine have been available since the 1970s in Europe and Canada, but Apokyn represents the first time any drug containing apomorphine has been approved for use in the US. It is indicated for the treatment of motor symptoms associated with late stage Parkinson's Disease.
It is specifically indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson’s disease, as adjunct/supplemental therapy to standard levodopa therapy. It is the first treatment approved for this indication in the US.
The recommended subcutaneous dose of Apokyn is 0.2 to 0.6 mL subcutaneously during acute hypomobility episodes, delivered via metered injector pen. Average dosing frequency during study was thrice daily, with a maximum studied regimen of 0.6 mL five times daily. Recommended application is to a pinch of skin on the upper arm, thigh or abdomen.
FDA approval of Apokyn for the treatment of acute Parkinsonian hypomobility was based on three randomized, controlled studies, enrolling a total of 108 subjects, all of whom had advanced Parkinson's disease (mean disease duration = 11.3 years) and were being treated with L-dopa and at least one other agent, usually a dopamine agonist. Improvement in motor function on the Unified Parkinson’s Disease Rating Scale (UPDRS) was the primary endpoint of all three studies. The trials enrolled a combined total of 108 subjects, including 29 (one trial) who had never received apomorphine products (the remaining 79 subjects had experience internationally with apomorphine). Results showed that Apokyn was significantly efficacious in ending hypomotor episodes and markedly impoving UPDRS motor scores (> 20 points mean improvement for all trials) 20 minutes after dosing, compared with placebo (p<0.0001 for all trials). 98% of all trial subjects began antiemetic treatment with Tigan (trimethobenzamide) 3 days prior to treatment; roughly 50% were able to eventually disontinue Tigan while continuing Apokyn treatment (mean time to discontinuation = 2 months).
Adverse events associated with the use of Apokyn may include (but are not limited to) the following:
In addition, Apokyn has been associated with a very high incidence on mild-to-moderate treatment-responsive nausea and/or vomiting, especially early in treatment while the subject is still acclimating to Apokyn. It is recommended that subjects begin antiemetic treatment with or just prior to treatment with Apokyn, and continue for as long as needed.
Apokyn injection delivers apomorphine hydrochloride hemihydrate, a non-ergoline dopamine agonist with high selectivity for the dopamine D4, D2, D3, D5 and adrenergic alpha-1D, alpha-2B, alpha-2C receptors, all of which are broadly associated with the promotion of motor function. The precise mechanism of action of Apokyn as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic D2 receptors within the caudate putamen, a brain stucture which supports motor function. Subcutaneous administration provides rapid, controlled systemic delivery, with linear pharmacokinetics over a doses ranging of 2 to 8 mg.
For additional information regarding Apokyn or hypomotor symptoms of advanced Parkinson's Disease, please contact the Apokyn Web Site
The Apokyn (apomorphine hydrochloride) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.